Comparative Pharmacology
Head-to-head clinical analysis: CAPOTEN versus ENALAPRIL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOTEN versus ENALAPRIL MALEATE.
CAPOTEN vs ENALAPRIL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, leading to decreased vasoconstriction, reduced aldosterone secretion, and increased plasma renin activity.
Enalapril is a prodrug that is hydrolyzed to enalaprilat, a potent competitive inhibitor of angiotensin-converting enzyme (ACE), blocking the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and sodium/water retention.
50 mg orally three times daily initially; maintenance 50-100 mg three times daily; maximum 450 mg/day.
Initial: 5 mg orally once daily; titrate to 10-40 mg/day in 1-2 divided doses. Target: 10-40 mg/day. Maximum: 40 mg/day. Route: Oral. Frequency: Once or twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.9 hours in healthy subjects, but prolonged in heart failure (up to 3-4 hours) and renal impairment (up to 5-10 hours).
Terminal elimination half-life of enalaprilat (active metabolite) is approximately 35-38 hours. This prolonged half-life supports once-daily dosing in most patients, but may require dosage adjustment in renal impairment.
Primarily renal (approximately 60-75% as unchanged drug and metabolites) and biliary/fecal (approximately 20%).
Primarily renal (60-80% as unchanged drug and metabolites, mainly enalaprilat); biliary/fecal excretion accounts for the remainder (approximately 20-30%).
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor